Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark. / Lynge, Elsebeth; Beau, Anna Belle; von Euler-Chelpin, My; Napolitano, George; Njor, Sisse; Olsen, Anne Helene; Schwartz, Walter; Vejborg, Ilse.

In: Breast Cancer Research and Treatment, Vol. 184, 2020, p. 891–899.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lynge, E, Beau, AB, von Euler-Chelpin, M, Napolitano, G, Njor, S, Olsen, AH, Schwartz, W & Vejborg, I 2020, 'Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark', Breast Cancer Research and Treatment, vol. 184, pp. 891–899. https://doi.org/10.1007/s10549-020-05896-9

APA

Lynge, E., Beau, A. B., von Euler-Chelpin, M., Napolitano, G., Njor, S., Olsen, A. H., ... Vejborg, I. (2020). Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark. Breast Cancer Research and Treatment, 184, 891–899. https://doi.org/10.1007/s10549-020-05896-9

Vancouver

Lynge E, Beau AB, von Euler-Chelpin M, Napolitano G, Njor S, Olsen AH et al. Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark. Breast Cancer Research and Treatment. 2020;184:891–899. https://doi.org/10.1007/s10549-020-05896-9

Author

Lynge, Elsebeth ; Beau, Anna Belle ; von Euler-Chelpin, My ; Napolitano, George ; Njor, Sisse ; Olsen, Anne Helene ; Schwartz, Walter ; Vejborg, Ilse. / Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark. In: Breast Cancer Research and Treatment. 2020 ; Vol. 184. pp. 891–899.

Bibtex

@article{78a7929a022f46439e869ebb8f338064,
title = "Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark",
abstract = "Introduction: Service breast cancer screening is difficult to evaluate because there is no unscreened control group. Due to a natural experiment, where 20{\%} of women were offered screening in two regions up to 17 years before other women, Denmark is in a unique position. We utilized this opportunity to assess outcome of service screening. Materials and methods: Screening was offered in Copenhagen from 1991 and Funen from 1993 to women aged 50–69 years. We used difference-in-differences methodology with a study group offered screening; a historical control group; a regional control group; and a regional–historical control group, comparing breast cancer mortality and incidence, including ductal carcinoma in situ, between study and historical control group adjusted for changes in other regions, and calculating ratios of rate ratios (RRR) with 95{\%} confidence intervals (CI). Data came from Central Population Register; mammography screening databases; Cause of Death Register; and Danish Cancer Register. Results: For breast cancer mortality, the study group accumulated 1,551,465 person-years and 911 deaths. Long-term breast cancer mortality in Copenhagen was 20{\%} below expected in absence of screening; RRR 0.80 (95{\%} CI 0.71–0.90), and in Funen 22{\%} below; RRR 0.78 (95{\%} CI 0.68–0.89). Combined, cumulative breast cancer incidence in women followed 8+ years post-screening was 2.3{\%} above expected in absence of screening; RRR 1.023 (95{\%} CI 0.97–1.08). Discussion: Benefit-to-harm ratio of the two Danish screening programs was 2.6 saved breast cancer deaths per overdiagnosed case. Screening can affect only breast cancers diagnosed in screening age. Due to high breast cancer incidence after age 70, only one-third of breast cancer deaths after age 50 could potentially be affected by screening. Increasing upper age limit could be considered, but might affect benefit-to-harm ratio negatively.",
keywords = "Breast cancer, Incidence, Mortality, Screening",
author = "Elsebeth Lynge and Beau, {Anna Belle} and {von Euler-Chelpin}, My and George Napolitano and Sisse Njor and Olsen, {Anne Helene} and Walter Schwartz and Ilse Vejborg",
year = "2020",
doi = "10.1007/s10549-020-05896-9",
language = "English",
volume = "184",
pages = "891–899",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

AU - Lynge, Elsebeth

AU - Beau, Anna Belle

AU - von Euler-Chelpin, My

AU - Napolitano, George

AU - Njor, Sisse

AU - Olsen, Anne Helene

AU - Schwartz, Walter

AU - Vejborg, Ilse

PY - 2020

Y1 - 2020

N2 - Introduction: Service breast cancer screening is difficult to evaluate because there is no unscreened control group. Due to a natural experiment, where 20% of women were offered screening in two regions up to 17 years before other women, Denmark is in a unique position. We utilized this opportunity to assess outcome of service screening. Materials and methods: Screening was offered in Copenhagen from 1991 and Funen from 1993 to women aged 50–69 years. We used difference-in-differences methodology with a study group offered screening; a historical control group; a regional control group; and a regional–historical control group, comparing breast cancer mortality and incidence, including ductal carcinoma in situ, between study and historical control group adjusted for changes in other regions, and calculating ratios of rate ratios (RRR) with 95% confidence intervals (CI). Data came from Central Population Register; mammography screening databases; Cause of Death Register; and Danish Cancer Register. Results: For breast cancer mortality, the study group accumulated 1,551,465 person-years and 911 deaths. Long-term breast cancer mortality in Copenhagen was 20% below expected in absence of screening; RRR 0.80 (95% CI 0.71–0.90), and in Funen 22% below; RRR 0.78 (95% CI 0.68–0.89). Combined, cumulative breast cancer incidence in women followed 8+ years post-screening was 2.3% above expected in absence of screening; RRR 1.023 (95% CI 0.97–1.08). Discussion: Benefit-to-harm ratio of the two Danish screening programs was 2.6 saved breast cancer deaths per overdiagnosed case. Screening can affect only breast cancers diagnosed in screening age. Due to high breast cancer incidence after age 70, only one-third of breast cancer deaths after age 50 could potentially be affected by screening. Increasing upper age limit could be considered, but might affect benefit-to-harm ratio negatively.

AB - Introduction: Service breast cancer screening is difficult to evaluate because there is no unscreened control group. Due to a natural experiment, where 20% of women were offered screening in two regions up to 17 years before other women, Denmark is in a unique position. We utilized this opportunity to assess outcome of service screening. Materials and methods: Screening was offered in Copenhagen from 1991 and Funen from 1993 to women aged 50–69 years. We used difference-in-differences methodology with a study group offered screening; a historical control group; a regional control group; and a regional–historical control group, comparing breast cancer mortality and incidence, including ductal carcinoma in situ, between study and historical control group adjusted for changes in other regions, and calculating ratios of rate ratios (RRR) with 95% confidence intervals (CI). Data came from Central Population Register; mammography screening databases; Cause of Death Register; and Danish Cancer Register. Results: For breast cancer mortality, the study group accumulated 1,551,465 person-years and 911 deaths. Long-term breast cancer mortality in Copenhagen was 20% below expected in absence of screening; RRR 0.80 (95% CI 0.71–0.90), and in Funen 22% below; RRR 0.78 (95% CI 0.68–0.89). Combined, cumulative breast cancer incidence in women followed 8+ years post-screening was 2.3% above expected in absence of screening; RRR 1.023 (95% CI 0.97–1.08). Discussion: Benefit-to-harm ratio of the two Danish screening programs was 2.6 saved breast cancer deaths per overdiagnosed case. Screening can affect only breast cancers diagnosed in screening age. Due to high breast cancer incidence after age 70, only one-third of breast cancer deaths after age 50 could potentially be affected by screening. Increasing upper age limit could be considered, but might affect benefit-to-harm ratio negatively.

KW - Breast cancer

KW - Incidence

KW - Mortality

KW - Screening

U2 - 10.1007/s10549-020-05896-9

DO - 10.1007/s10549-020-05896-9

M3 - Journal article

C2 - 32862304

AN - SCOPUS:85089973195

VL - 184

SP - 891

EP - 899

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -

ID: 248333929